Neramexane

• Description :

  Neramexane is an oral N-methyl-D-aspartate (NMDA) receptor antagonist, as a potential neuroprotectant for various central nervous system disorders, including Alzheimer's disease, and for the potential treatment of drug and alcohol dependence, and pain.

• UNSPSC :

  12352211

• Hazard Statement :

  H315-H319-H320

• Target :

  IGluR

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Assay Protocol :

  https://www.medchemexpress.com/neramexane.html

• Smiles :

  NC1(C)CC(C)(C)CC(C)(C)C1

• Molecular Formula :

  C11H23N

• Molecular Weight :

  169.31

• Precautions :

  P264-P280-P302+P352-P305+P351+P338-P362

• References & Citations :

  [1]Rammes G. Neramexane: a moderate-affinity NMDA receptor channel blocker: new prospects and indications. Expert Rev Clin Pharmacol. 2009;2 (3) :231-238. |[2]Plazas PV, Savino J, Kracun S, et al. Inhibition of the alpha9alpha10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-D-aspartate receptors. Eur J Pharmacol. 2007;566 (1-3) :11-19. |[3]Wenk GL, Baker LM, Stoehr JD, Hauss-Wegrzyniak B, Danysz W. Neuroprotection by novel antagonists at the NMDA receptor channel and glycineB sites. Eur J Pharmacol. 1998;347 (2-3) :183-187.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• CAS Number :

  [219810-59-0]